{"id":"tetanus-toxoid-adsorbed-vaccine","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108876","moleculeType":"Vaccine component"},"_dailymed":{"setId":"67d5c665-ca88-49ba-b7d3-7145d9878cf0","title":"PENTACEL (DIPHTHERIA AND TETANUS TOXOIDS AND ACELLULAR PERTUSSIS ADSORBED, INACTIVATED POLIOVIRUS AND HAEMOPHILUS B CONJUGATE (TETANUS TOXOID CONJUGATE) VACCINE) KIT [SANOFI PASTEUR INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated tetanus toxin (toxoid) adsorbed onto an aluminum salt adjuvant, which enhances the immune response. When administered, it triggers B and T cell responses that generate protective antibodies (antitoxins) against tetanus toxin produced by Clostridium tetani. This provides long-term immunity against tetanus disease.","oneSentence":"Tetanus toxoid adsorbed vaccine stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against tetanus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:55.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against tetanus"},{"name":"Tetanus prophylaxis and booster immunization"}]},"trialDetails":[{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT02992925","phase":"PHASE3","title":"Phase 3 Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11","conditions":"Immunization; Infection","enrollment":370},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT02118961","phase":"PHASE3","title":"Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":446},{"nctId":"NCT03188692","phase":"PHASE3","title":"Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-06-23","conditions":"Immunization","enrollment":33},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT06588530","phase":"PHASE4","title":"PFAS Exposure and Immune Response to Vaccination in Adults","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-11-04","conditions":"Innate Inflammatory Response, Vaccination, Diphtheria","enrollment":20},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT06639074","phase":"PHASE2","title":"Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-11-08","conditions":"Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma","enrollment":78},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT03890367","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-12","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":707},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04300192","phase":"PHASE4","title":"Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-01-27","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":273},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT06857370","phase":"PHASE3","title":"Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-03-23","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":780},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT03299309","phase":"PHASE1","title":"PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daniel Landi","startDate":"2018-06-29","conditions":"Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma","enrollment":30},{"nctId":"NCT05662852","phase":"PHASE2","title":"Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors","status":"COMPLETED","sponsor":"ABO Holdings, Inc.","startDate":"2023-05-05","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination","enrollment":100},{"nctId":"NCT03589768","phase":"PHASE2","title":"Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-01-24","conditions":"Clostridium Difficile Immunisation, Diphtheria, Diphtheria Immunisation","enrollment":399},{"nctId":"NCT04658914","phase":"PHASE2","title":"Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa","status":"COMPLETED","sponsor":"Centre for Infectious Disease Research in Zambia","startDate":"2021-04-15","conditions":"Diarrhea, Diarrhea Rotavirus","enrollment":720},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT06056050","phase":"PHASE1","title":"A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":180},{"nctId":"NCT06708286","phase":"PHASE2, PHASE3","title":"A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1820},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT06817187","phase":"PHASE3","title":"Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-16","conditions":"Streptococcus Pneumoniae Infections","enrollment":1110},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT06120751","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Tetanus","enrollment":1000},{"nctId":"NCT06123663","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-20","conditions":"Tetanus","enrollment":60},{"nctId":"NCT06607380","phase":"PHASE1","title":"A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine","status":"COMPLETED","sponsor":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","startDate":"2022-08-13","conditions":"Tetanus","enrollment":60},{"nctId":"NCT06049940","phase":"PHASE3","title":"Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-09-01","conditions":"Tetanus","enrollment":1260},{"nctId":"NCT06360250","phase":"EARLY_PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-04-10","conditions":"Clostridium Tetanus","enrollment":190},{"nctId":"NCT03927222","phase":"PHASE2","title":"Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma","status":"TERMINATED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2019-09-30","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT02193347","phase":"PHASE1","title":"IDH1 Peptide Vaccine for Recurrent Grade II Glioma","status":"COMPLETED","sponsor":"Katy Peters, MD, PhD","startDate":"2016-01-28","conditions":"Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent","enrollment":24},{"nctId":"NCT05870618","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT05870631","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT01644968","phase":"PHASE1","title":"Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2003-11","conditions":"Advanced Cancer","enrollment":30},{"nctId":"NCT01137435","phase":"PHASE4","title":"Post Marketing Surveillance for ADACEL™ in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":659},{"nctId":"NCT01439165","phase":"PHASE4","title":"Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-11","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":1330},{"nctId":"NCT03958799","phase":"PHASE1","title":"A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-06-26","conditions":"Tetanus Immunisation (Healthy Volunteers), Diphtheria Immunisation (Healthy Volunteers), Pertussis Immunisation (Healthy Volunteers)","enrollment":71},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01437423","phase":"PHASE4","title":"Regulatory Post-Marketing Surveillance Study for TETRAXIM™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":600},{"nctId":"NCT02992418","phase":"PHASE3","title":"Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-12-19","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":688},{"nctId":"NCT02587520","phase":"PHASE1, PHASE2","title":"Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-10-22","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":1363},{"nctId":"NCT01187433","phase":"PHASE2","title":"Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":150},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00006066","phase":"PHASE1","title":"Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT03063736","phase":"EARLY_PHASE1","title":"Entolimod, an Adjuvant for Vaccine Augmentation","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2017-12-08","conditions":"Substance Use Disorders","enrollment":40},{"nctId":"NCT00553228","phase":"PHASE2, PHASE3","title":"Pertussis Maternal Immunization Study","status":"COMPLETED","sponsor":"Scott Halperin","startDate":"2007-11","conditions":"Pregnant Women","enrollment":320},{"nctId":"NCT03197376","phase":"PHASE3","title":"Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2017-06-21","conditions":"Pneumonia, Pneumococcal","enrollment":2250},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT04056728","phase":"PHASE4","title":"A Phase IV Study to Assess the Safety of EupentaTM Inj","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-09-23","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection","enrollment":3000},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT00385255","phase":"PHASE3","title":"Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-23","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":1726},{"nctId":"NCT03931239","phase":"NA","title":"The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks","status":"COMPLETED","sponsor":"Vabiotech","startDate":"2018-03-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":222},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01764256","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-12","conditions":"Rotavirus Infection","enrollment":48},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01174849","phase":"PHASE4","title":"Pneumococcal Vaccines Early and in Combination","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2011-08","conditions":"Otitis Media","enrollment":425},{"nctId":"NCT02858570","phase":"PHASE2, PHASE3","title":"Conjugate Vaccine Against Meningococcus C a Brazilian Project","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2018-09-25","conditions":"Serogroup C Meningococcal Meningitis","enrollment":1644},{"nctId":"NCT00282295","phase":"PHASE4","title":"US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-25","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":1344},{"nctId":"NCT00258882","phase":"","title":"Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-01","conditions":"Pertussis","enrollment":327293},{"nctId":"NCT00000105","phase":"","title":"Vaccination With Tetanus and KLH to Assess Immune Responses.","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-07","conditions":"Cancer","enrollment":112},{"nctId":"NCT02589678","phase":"PHASE1, PHASE2","title":"Zambia SiVET MMR Tdap-IPV","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-08","conditions":"High Risk for HIV","enrollment":160},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT01249183","phase":"PHASE3","title":"Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":954},{"nctId":"NCT00447525","phase":"PHASE3","title":"REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-02","conditions":"Diphtheria, Tetanus, Poliomyelitis","enrollment":760},{"nctId":"NCT00282308","phase":"PHASE2","title":"A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01-23","conditions":"Rheumatoid Arthritis","enrollment":103},{"nctId":"NCT02089347","phase":"PHASE3","title":"Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-03","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":534},{"nctId":"NCT01711645","phase":"PHASE4","title":"Tdap Vaccine in Post-Partum Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10-26","conditions":"Diphtheria, Pertussis, Tetanus","enrollment":55},{"nctId":"NCT00289913","phase":"PHASE4","title":"Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Hepatitis A Virus","enrollment":1274},{"nctId":"NCT00343421","phase":"PHASE3","title":"Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":588},{"nctId":"NCT00654901","phase":"PHASE3","title":"Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":881},{"nctId":"NCT00802867","phase":"PHASE4","title":"Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":989},{"nctId":"NCT00258895","phase":"PHASE3","title":"Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":649},{"nctId":"NCT00601835","phase":"PHASE4","title":"Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-05","conditions":"Diphtheria, Tetanus","enrollment":3651},{"nctId":"NCT01311557","phase":"PHASE4","title":"Study of Adacel® Vaccine Administered to Persons 10 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":1302},{"nctId":"NCT01529645","phase":"PHASE1","title":"Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-03","conditions":"Pertussis, Whooping Cough, Tetanus","enrollment":420},{"nctId":"NCT02382913","phase":"PHASE1","title":"Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)","status":"COMPLETED","sponsor":"Novartis","startDate":"2015-04","conditions":"Pertussis","enrollment":315},{"nctId":"NCT01933776","phase":"PHASE1","title":"Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-08","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":40},{"nctId":"NCT01629589","phase":"PHASE4","title":"Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-06","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":423}],"_emaApprovals":[],"_faersSignals":[{"count":70,"reaction":"DRUG HYPERSENSITIVITY"},{"count":52,"reaction":"FATIGUE"},{"count":50,"reaction":"ARTHRALGIA"},{"count":49,"reaction":"MALAISE"},{"count":48,"reaction":"PAIN"},{"count":43,"reaction":"PYREXIA"},{"count":38,"reaction":"NAUSEA"},{"count":36,"reaction":"DYSPNOEA"},{"count":35,"reaction":"DRUG INEFFECTIVE"},{"count":35,"reaction":"FOETAL EXPOSURE DURING PREGNANCY"}],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tetanus Toxoid Adsorbed Vaccine","genericName":"Tetanus Toxoid Adsorbed Vaccine","companyName":"Genentech, Inc.","companyId":"genentech-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tetanus toxoid adsorbed vaccine stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against tetanus infection. Used for Active immunization against tetanus, Tetanus prophylaxis and booster immunization.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}